EKSO BIONICS HOLDINGS, INC.

1.** Organization

Description of Business

Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton and complementary products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI") to rehabilitate and to stand and walk in neurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in2005**, the Company is headquartered in the San Francisco Bay Area and listed on the Nasdaq Capital Market under the symbol “EKSO”.

Unless otherwise indicated, all dollar and share amounts included in these notes to the condensed consolidated financial statements are in thousands.

All common stock share and per share amounts have been adjusted to reflect theone-for-fifteen reverse stock split effected on* June 2, 2025.See Note11.* Capitalization and Equity Structure – Reverse Stock Split for additional information.

Liquidity and Going Concern

As of* March 31, 2026*, the Company had an accumulated deficit of $269,281. The Company has incurred significant operating losses and negative cash flows from operations since inception. During thethree months ended* March 31, 2026*, the Company used $2,123 of cash in its operations. Cash on hand as of* March 31, 2026* was $3,993.

On* January 12, 2026,the Company entered into an irrevocable standby letter of credit (the "letter of credit"), established by its primary operating bank, in favor of the Company'sthird*-party contract manufacturer, as the beneficiary, in the aggregate amount of $250, effective* January 12, 2026and expiring on January 12, 2027,unless otherwise extended or terminated. The purpose of the letter of credit is to provide financial security to thethird*-party contract manufacturer for inventory procurement and manufacturing obligations. As the letter of credit requires the Company to maintain a corresponding cash deposit with its bank, the full amount is classified as restricted cash as a component of Cash and restricted cash in the Company's condensed consolidated balance sheet as of* March 31, 2026.After considering cash restrictions, effective unrestricted cash as of March 31, 2026*was approximately $3,743.

Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period ofone year after the date that the condensed consolidated financial statements are issued. Management intends to raise funds throughone or more financings in the near term in order to meet our cash requirements for the next12 months. However, due to several factors, including those outside management’s control, there can beno assurance that the Company will be able to complete such financings on acceptable terms or in amounts sufficient to continue operating the business under the operating plan. As part of the financing strategy, management is simultaneously pursuing strategic partnerships, delaying or abandoning certain product development projects, cost reduction efforts for our products, and refocusing sales efforts to accelerate revenue growth above historical results. We have concluded the likelihood that our plan to successfully reduce expenses to align with our available cash, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least12 months from the date of issuance of these condensed consolidated financial statements. Management currently estimates that the Company's cash on hand as of* March 31, 2026will fund its operations into the early part of thethird* quarter of2026.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements donot include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

9

2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates

Basis of Presentation and Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form10-K for the fiscal year ended* December 31, 2025*, which was filed with the SEC on* February**23,* 2026.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended* December 31, 2025*, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for thethree months ended* March 31, 2026* arenot necessarily indicative of the results to be expected for the year ending* December 31, 2026* or any future periods.

The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but arenot limited to, intangible and tangible assets acquired and liabilities assumed in business combinations, revenue recognition, deferred revenue, the provision for credit losses on accounts receivable, the valuation of convertible preferred stock and warrants, employee equity awards, phantom performance-based restricted stock units, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

10

Inventories

Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on afirst-in,first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the condensed consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typicallynot readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset* may*be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of12 months or less arenot recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.

Phantom Performance-Based Restricted Stock Valuation

On* November 5, 2025,the Company issued 257 phantom performance-based restricted stock units ("Phantom PSUs") in total to its executive officers in order to assist in retention, drive stockholder growth, and achieve the Company's strategic goals. Each award of the Phantom PSUs is scheduled to vest upon achievement of each of the followingtwo* performance requirements within thefive-year period following the date of grant, in each case subject to the applicable executive officers' continued employment through the applicable date of achievement: (i) the occurrence of a change in control, and (ii) achievement of a stock price of at least $7.50.

As of both the grant date and* March**31,* 2026, the Company determined that the change in control condition, or triggering event, of the Phantom PSUs wasnot probable. If the change in control condition is deemed to be probable as of a future reporting date, the Company would account for the Phantom PSUs as a liability due to their settlement in cash, based on the estimated fair value measured at each reporting date, in accordance with ASC718, Compensation—Stock Compensation. Subsequently, the Company would record changes in the estimated fair value as a component of operating expenses in the condensed consolidated statements of operations and comprehensive loss. As long as the Company considers the change in control condition to be probable as of the reporting date, the Phantom PSUs will be remeasured at fair value until settlement, which are to be settled in cash only.

The fair values of these Phantom PSUs will be determined using the Monte Carlo simulation model. The Monte Carlo simulation model requires inputs, such as the expected volatility, expected term, risk-free interest rate, and the value of the underlying security. The Monte Carlo simulation model provides for assumptions regarding expected volatility, expected term, risk-free interest rates, the value of the underlying security, and the probability of and likely timing of a specific event within the expected term. These values are subject to a significant degree of judgment. The Company’s common stock price represents a significant input that affects the valuation of the Phantom PSUs. Changes in these assumptions could have potential material impacts on the estimated fair value of the Phantom PSU liabilities.

When the triggering events are determined to be probable, the fair values, representing the expected cash settlement of the Phantom PSUs, will be included as a component of operating expenses, under the captions "General and administrative" and "Research and development," in the condensed consolidated statements of operations and comprehensive loss, and the corresponding liability will be included as a component of Accrued liabilities in the condensed consolidated balance sheets.

Revenue Recognition

The Company records its revenue in accordance with ASC606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the followingfive steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price isnot directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of customer. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company generally doesnot grant a right of return for its products. The Company exercised judgement to determine that a product return reserve wasnot required as of* March 31, 2026* and* December 31, 2025*, as historical returns activity hasnot been material and the Company's expectations and estimates regarding future returns havenot changed.

11

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable.

The Company's cash balances held in domestic banks are deposited into accounts at various institutions with each balance under the*$250* Federal Deposit Insurance Corporation ("FDIC") insurance limit. The Company has significant cash balances at foreign financial institutions which regularly exceed the applicable country cash deposit insurance limits of approximately*$100* at each of the Company'stwo foreign banks. Any foreign exchange loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company doesnot require collateral from its customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the United States, Europe, and Asia. Invoices are aged based on contractual terms with the customer.

Many of the sales contracts with customers outside of the United States are settled in a foreign currency other than the U.S. dollar. The Company doesnot enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company hasnot experienced significant gains or losses upon collecting receivables denominated in a foreign currency.

The Company hadthree customers with an accounts receivable balance totaling10% or more of the Company’s total accounts receivable as of* March 31, 2026* (14%,13%,11%), as compared withone customer as of* December 31, 2025* (29%).

During thethree months ended* March 31, 2026*, the Company hadtwo customers with sales of10% or more of the Company’s total revenue (16% and 15%), as compared withtwo customers in thethree months ended* March 31, 2025* (12% and 12%).

Accounts Receivable and Allowance for Credit Losses

The Company carries accounts receivable at invoiced amounts less an allowance (or "provision") for credit losses. The Company reviews accounts receivable for collectability and determines an allowance for potential credit losses. The allowance for credit losses on accounts receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on historical bad debt expense, the aging of the accounts, known troubled accounts, and customer payment history. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within30 to120 days. Accounts receivables are charged off after all reasonable means to collect the full amount, including litigation where appropriate, have been exhausted. During thethree months ended* March 31, 2026,the Company recorded $298 in bad debt expense primarily related to the specific identification of certain uncollectible balances from a single counterparty, which is included as a component of operating expenses, under the caption "Sales and marketing," in the consolidated statement of operations and comprehensive loss. The Company hasnot* experienced any other material losses related to accounts receivable during thethree months ended* March 31,2026. The Company hasnot experienced material losses related to accounts receivable during thethree months ended March 31,2025. The Company's accounts receivable balances, net of allowances, as of March 31, 2026*,* December 31, 2025*, and* December 31, 2024*were $4,537, $7,308, and $7,238, respectively.

Employee Retention Credit

On* March 27, 2020,in response to the COVID-19 pandemic, the U.S. Congress enacted the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The CARES Act, along with other subsequent federal acts that extended the aid, allowed eligible employers to claim employee retention credits (“ERC”) for qualified wages paid after March 12, 2020and before January 1, 2022.We qualified for credits under the provisions of the CARES Act for the entire period subsequent to January 1, 2021,through June 30, 2021.The Company elected to account for the ERC as a government grant. As there isno* authoritative guidance under U.S. GAAP on accounting for grants to for-profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic20, Accounting for Government Grants and Disclosure of Government Assistance(“IAS20"). Under IAS20, government grants are recognized when there is reasonable assurance that the grant will be received and that all conditions related to the grant will be met.

Accounting Pronouncements Adopted in2026**

In* July 2025,the FASB issued Accounting Standards Update ("ASU")No. 2025-05, Financial Instruments—Credit Losses (Topic326*): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU2025-05”), which provides a practical expedient for estimating expected credit losses for current accounts receivable and current contract assets. For thethree months ended* March 31, 2026,the Company adopted ASU2025*-05 on a prospective basis. Upon adoption, the Company elected to apply the practical expedient to estimate its allowance for credit losses by assuming current conditions—as of the most recent balance sheet date—remain constant throughout the remaining life of the Company's accounts receivable balances. The Company continues to adjust historical loss information for current conditions as it relates to the allowance for credit losses. The adoption of ASU2025-05 didnot have a material impact on the Company's condensed consolidated financial statements and related disclosures.

Recent Accounting Pronouncements

In* December 2025,the FASB issued ASUNo.* 2025-11, Interim Reporting (Topic270): Narrow-Scope Improvements ("ASU2025-11"), which clarifies interim disclosure requirements and the applicability of Topic270. The guidance will be effective for interim periods beginning after* December 15, 2027,with early adoption permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of this pronouncement on its related consolidated financial statements and disclosures and doesnot* expect to early adopt.

In* November 2024,the FASB issued ASUNo.* 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic220-40): Disaggregation of Income Statement Expenses (“ASU2024-03”), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s fiscal years beginning after* December 15, 2026,and interim periods beginning after December 15, 2027,with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related consolidated disclosures and doesnot* expect to early adopt.

12

3. Accumulated Other Comprehensive (Loss) Income

The Company's accumulated other comprehensive (loss) income consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments.

The change in accumulated other comprehensive (loss) income presented on the condensed consolidated balance sheets for thethree months ended* March 31, 2026* and2025 is reflected in the table below net of tax:

4. Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which thefirst two are considered observable and the last unobservable,* may*be used to measure fair value which are the following:

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:

During thethree months ended* March 31, 2026* and2025, there wereno transfers between Level1, Level2, or Level3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used didnot change compared to the Company’s established practice.

The following table sets forth a summary of the changes in the fair value of the Company’s Level3 financial liabilities for thethree months ended* March 31, 2026*, which were measured at fair value on a recurring basis:

Refer to Note11.** Capitalization and Equity Structure–* Warrants* for additional information regarding the valuation of warrants.

5. Inventories

Inventories as of* March 31, 2026* and* December 31, 2025* consisted of the following:

6. Revenue

The Company’s revenue is primarily generated through the sale of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, along with the sale of support, maintenance, and subscription contracts. Revenue from device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of these devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements ranging from 12 to 48 months. Revenue is recognized evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over24 months.

Deferred Revenue

Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.

Deferred revenue consisted of the following:

13

Deferred revenue transactions consisted of the following for thethree months ended* March 31, 2026*:

The Company expects to recognize approximately $1,321 of the deferred revenue during the remainder of 2026, $865 in 2027, and $658 thereafter.

In addition to deferred revenue, the Company has a non-cancellable backlog of $556 expected to be recognized across2026, 2027, and2028, which includes customer orders received butnot fulfilled and other ancillary products and services of $244, and contracts for subscription units of $312.

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source for thethree months ended* March 31, 2026*:

The following table disaggregates the Company’s revenue by major source for thethree months ended* March 31, 2025*:

14

The Company operates in the following regions: (1) Americas, (2) Europe, the Middle East, and Africa ("EMEA"), and (3) Asia Pacific ("APAC"). Individual countries with revenue greater than10% of total revenue for thethree months ended* March 31, 2026and2025* are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:

7. Accrued Liabilities

Accrued liabilities as of* March 31, 2026* and* December 31, 2025* consisted of the following:

Warranty

Sales of devices generally include an initial warranty for parts and services forone totwo years in the Americas,two years in EMEA, andone tothree years in APAC. Warranty costs are reflected in the condensed consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for thethree months ended* March 31, 2026* is as follows:

15

8. Goodwill and Intangible Assets

On* December 5, 2022,*the Company acquired the Human Motion Control ("HMC") business unit from Parker (the "HMC Acquisition"). The assets acquired from the business unit included intellectual property rights associated with the Ekso Indego Personal, Ekso Indego Therapy, Nomad, and future products in the orthotics and prosthetics space.

Goodwill

The Company accounted for the acquisition as a business combination in accordance with ASC805, Business Combinations, by applying the acquisition method, and accordingly, the purchase price was allocated to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the purchase price over the net assets acquired of $431 was recorded as goodwill. The goodwill recognized is attributed primarily to expected synergies of HMC with the Company.

The Company determinedno impairment existed for goodwill for thethree months ended* March 31, 2026* and2025.

Intangible Assets

The following table summarizes the components of initial gross intangible assets, accumulated amortization and impairment, and net carrying values for definite- and indefinite-lived intangible asset balances as of* March 31, 2026* and* December 31, 2025*:

16

Definite-lived intangible assets are amortized over their estimated lives using the straight-line method, which is estimated aseight years for developed technology,12 years for intellectual property andeight years for customer relationships. The acquired trade name was estimated to have an indefinite life, and consequently,no amortization expense was recorded.

The Company determinedno impairment existed for its intangible assets for thethree months ended* March 31, 2026*.

In thefourth quarter of2025, the Company completed its annual quantitative impairment analysis for its indefinite-lived trade name and finite-lived intangible assets. The quantitative impairment analysis for the Company's trade name asset consists of a comparison of the fair value of the asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of the trade name asset using the relief-from-royalty method, a form of the income approach, which the Company believes is an appropriate and widely used valuation method of such assets in nature. The trade name asset represents the Company's identity and brand recognition associated with the products acquired in the HMC Acquisition. The valuation method is based on the assumption that, in lieu of ownership, a firm would be willing to pay a royalty in order to exploit the related benefits of the asset class. Significant estimates in valuing the Company's trade name asset include, but arenot limited to, the amount and timing of projected future cash flows based on expected future growth rates and margins, discount rate used to determine the present value of these cash flows, and royalty rate for similar brand licenses. The fair value derived from the relief-from-royalty method is measured as the discounted cash flow savings realized from owning such trade names andnot being required to pay a royalty for their use. Based on the impairment test completed, the Company concluded that the carrying value of the trade name asset exceeded its estimated fair value due to downward revisions to the Company's short-term and long-term revenue forecasts, and as a result, recognized a $570 impairment loss for its trade name asset in the period, which reduced the asset balance to $1,740 as of* December 31, 2025.The impairment loss was included as a component of operating expenses, under the caption "Sales and marketing," in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2025.*

Based on the impairment tests completed in thefourth quarter of2025 for the Company's finite-lived intangible assets, including its developed technology assets, the Company concluded that the estimated fair value of such assets exceeded its carrying value, and as a result,no impairment loss was recognized in the period.

The Company had a Knee License Agreement with Vanderbilt University ("Vanderbilt") to maintain exclusive rights to patents on the Company's behalf (the "License Agreement"). On* April 16, 2025,the Company executed a Termination Agreement with Vanderbilt of the License Agreement (the "Termination Agreement"). Per the Termination Agreement, the Company isno* longer required to pay 3.75% of net sales for its Swing-Assist Microprocessor-Controlled Knee ("SA-MPK") licensed patent products and a minimum annual royalty of $75 due on or before* July 31, 2028and $100 per year thereafter until February 15, 2041.Under the Termination Agreement, should, to the extent Vanderbilt successfully licenses the rights of the SA-MPK technology to athird*-party, Vanderbilt will pay the Company 50% of Vanderbilt's share of any net revenues attributable to the rights received from such future license agreement until $100 has been paid to the Company. As a result of the overall uncertainty of the future revenues, the Company performed an impairment assessment of the intangible asset as of* March* 31, 2025. In estimating the fair value of the asset, the Company utilized the undiscounted cash flow model, dependent on the primary assumption of forecasted revenues from the quoted market price of the Termination Agreement, which led to a $180 impairment loss recognized for the asset in the period, and reduced the asset balance to $0. The impairment loss was included as a component of operating expenses, under the caption "General and administrative," in the consolidated statement of operations and comprehensive loss for the year ended* December* 31, 2025.

The Company determinedno impairment existed for its other intangible assets for thethree months ended* March 31, 2025.*

The estimated future amortization expenses related to definite-lived intangible assets as of* March 31, 2026* were as follows:

Amortization expense related to the acquired definite-lived intangible assets was $82 and $82 for thethree months ended* March 31, 2026* and2025, respectively, and was included as a component of cost of revenue ($78 and $78, respectively) and operating expenses ($4 and $4, respectively) in the condensed consolidated statement of operations and comprehensive loss.

9. Notes Payable, net

B. Riley Promissory Note

On* September**12,* 2025, the Company entered into a Secured Promissory Note and Security Agreement (the “B. Riley Promissory Note”) with B. Riley Commercial Capital, LLC ("B. Riley") as lender. The B. Riley Promissory Note provides for a secured term loan in an aggregate principal amount of up to $2,000. The Company is using the net proceeds from the B. Riley Promissory Note for working capital for operations and other general corporate purposes. The loan matures on the earlier of the receipt of at least $2,400 in net proceeds from the sale of the equity interests of the Company from new equity investors (a “Qualified Financing”), or* September 14, 2026 (the “Maturity Date”). The Company has received a waiver under the B. Riley Promissory Note such that the business combination pursuant to the Contribution and Exchange Agreement dated as of February 15, 2026and certain related transactions donot* constitute an Event of Default (as defined under the B. Riley Promissory Note).

Borrowings under the B. Riley Promissory Note bear interest at the rate of 10% per annum, which shall be payable in full on the Maturity Date. On the Maturity Date, the Company shall pay to B. Riley an exit fee in the amount of 10% of the original principal amount of the loan, which shall in the aggregate be $200 (the “Exit Fee”). The Company* mayprepay the obligations under the B. Riley Promissory Note at any time in whole or in part. In connection with such prepayment, the Company must pay all accrued but unpaid interest on such portion of the principal prepaid, all interest that would have accrued through the Maturity Date on such principal amount prepaid and the portion of the Exit Fee applicable to such principal amount prepaid. B. Riley may*elect to convert the obligations under the B. Riley Promissory Note, including the principal, interest, and Exit Fee, into equity securities of the Company in connection with a Qualified Financing at the purchase price per share paid by the lead investor thereunder.

The obligations under the B. Riley Promissory Note are required to be guaranteed by Ekso Bionics, Inc., a Delaware corporation and subsidiary of the Company (the "Subsidiary"), and secured by substantially all of the personal property of the Company and the Subsidiary. The B. Riley Promissory Note also contains customary affirmative and negative covenants, including negative covenants limiting the ability of the Company and the Subsidiary to, among other things, incur debt, grant liens, dispose of assets, and make certain restricted payments, in each case, subject to limitations and exceptions set forth in the B. Riley Promissory Note. As of* March 31, 2026*, the Company was compliant with all covenants.

The B. Riley Promissory Note contains various customary events of default that include, among others, non-payment of principal, interest or fees, breach of covenants, inaccuracy of representations and warranties, cross defaults to certain other indebtedness, cross default to contractual obligations, occurrence of a material adverse effect, bankruptcy and insolvency events, material judgments, and events constituting a change of control, subject to thresholds and cure periods as set forth in the B. Riley Promissory Note. Upon the occurrence and during the continuance of an event of default, B. Riley* mayaccelerate the Company’s obligations under the B. Riley Promissory Note (including the Exit Fee and all interest that would have been due on the Maturity Date) and may*exercise certain other rights and remedies provided for under the B. Riley Promissory Note, the other loan documents and applicable law. Under certain circumstances, a default interest rate will apply on all obligations during the existence of an event of default under the B. Riley Promissory Note at a per annum rate equal to 5% above the otherwise applicable interest rate.

The Company recorded the B. Riley Promissory Note of $2,000 in its condensed consolidated balance sheets under the caption Convertible promissory note, net.

The Company recognized $76 in debt issuance costs, which were recorded as a discount to the Convertible promissory note.

The following table presents the principal amount, debt premium and Exit Fee, and carrying value of the Company's B. Riley Promissory Note as of* March 31, 2026*, which were classified as current:

The effective interest rate for the period from the date of issuance through* March 31, 2026* was 22.6%. The debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan. Since the Exit Fee is mandatory, it was included in the cash flows used to apply the effective interest method and will result in an additional liability of $200 upon loan repayment. The following table sets forth the total interest expense recognized for thethree months ended* March 31, 2026*:

As of* March**31,* 2026, the B. Riley Promissory Note had accrued interest of $110.

The Company evaluated the B. Riley Promissory Note and determined that certain redemption features met the definition of an embedded derivative liability that are required to be bifurcated from the host instrument. However, since the conversion option didnot include a discount on the price per share or have a fixed conversion price, and the full interest and Exit Fee are guaranteed regardless of the timing of the event, the fair value of the compound embedded derivative was determined to haveno value. Therefore,no derivative liability was recorded.

BoC Term Loan

In* August 2020,the Company entered into a loan agreement (the "BoC Loan Agreement") with Pacific Western Bank, which merged with the Banc of California (the "Lender") in2024.* The Company received a loan in the principal amount of $2,000 (the "BoC Term Loan") that bore interest on the outstanding daily balance at a rate equal to the greater of: (a)0.50% above the variable rate of interest announced by the Lender as its “prime rate” then in effect; or (b)4.50%. The BoC Loan Agreement created afirst priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

The Company was required to pay accrued interest on the current loan on the13th day of each month through and including* August 13, 2023,at which time the unpaid principal and accrued and unpaid interest was due and payable in full. On August 17, 2023,the Company entered into an amendment to the BoC Loan Agreement, extending the maturity date to August 13, 2026with interest only payments until such date, having daily borrowings bearing interest at a variable annual rate equal to the greater of the Lender's "prime rate" then in effect and 4.50%, and caused the Company to maintain all of its depository, operating, and investment accounts with the Lender. The Company determined this amendment constituted a loan modification under ASC470,* and used the updated imputed interest rate to recalculate debt discounts, debt issuance costs and final payment to be amortized over the new term.

On* September 12, 2025,in connection with the entry into the B. Riley Promissory Note, the Company paid off all obligations under and terminated the BoC Loan Agreement. The BoC Loan Agreement contained a liquidity covenant, which required that the Company maintain cash in accounts of the Lender or subject to control agreements in favor of the Lender in an amount equal to at least the outstanding balance of the BoC Term Loan, which was $2,000. It also contained a primary depository covenant, which restricted the Company from having more than $1,000 held in subsidiary bank accounts outside of the United States. As of September 12, 2025,*these covenants were terminated.

The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 7.64% for thethree months ended* March 31, 2025.The debt issuance costs and debt discounts were amortized to interest expense using the effective interest method over the life of the loan. Interest expense for the BoC Term Loan totaled $38 for thethree* months ended* March 31, 2025.There wereno comparable amounts for thethree* months ended* March 31, 2026.*

17

Parker Hannifin Promissory Note

In connection with the HMC Acquisition, on* December 5, 2022,the Company delivered a $5,000 unsecured, subordinated promissory note (the "Parker Hannifin Promissory Note") to Parker. The Parker Hannifin Promissory Note, which is subordinate to the B. Riley Promissory Note, bearsno interest with principal payable insixteen equal installments due on the last day of each quarter, which commenced on December 31, 2023and matures on September 30, 2027.*

The Parker Hannifin Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a)5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Parker Hannifin Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity.

The Company recorded the Parker Hannifin Promissory Note of $4,055 in its condensed consolidated balance sheets under the captions Notes payable, current and Notes payable, net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's BoC Term Loan and other relevant economic factors present at the execution date of the Parker Hannifin Promissory Note. The amortization of debt discounts resulted in an effective interest rate of 6.63% and 6.86% for thethree months ended* March 31, 2026* and2025, respectively. The debt discount is amortized to interest expense using the effective interest method over the life of the loan. Interest expense on the Parker Hannifin Promissory Note was $35 and $54 for thethree months ended* March 31, 2026* and2025, respectively.

The following table presents scheduled principal payments of the Company's Parker Hannifin Promissory Note as of* March 31, 2026*:

18

10. Lease Obligations

The Company's operating lease agreement for its headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") commenced in* July 2022and expires in November* 2026, and it provides the Company with the option to renew for an additional three-year period at the prevailing market rate at the time of extension.

The San Rafael Lease constitutes an operating lease under ASC842 and the Company estimates the lease term as* July 2022through November**2026.* The option to extend for athree-year period lacks significant economic incentives and disincentives, which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for the San Rafael Lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company's operating lease agreement for its service facility in Brecksville, Ohio (the "Ohio Lease") commenced in* June 2024and expires in July 2027.In thesecond* half of2025, the Company transitioned manufacturing of its Ekso Indego Therapy and Ekso Indego Personal products from its facility in Brecksville, Ohio to its facility in San Rafael, California. In* March 2026,*in connection with the Company's consolidation of manufacturing and servicing of its Ekso Indego products to San Rafael, California, the Company fully vacated the Brecksville, Ohio facility.

The Company has determined that the Ohio Lease constitutes an operating lease under ASC842 and estimates the lease term as* July 2024through July* 2027. Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities. As of* March 2026,the Company determined that the Ohio Lease was abandoned under ASC842,* as the Company ceased use of the Brecksville, Ohio facility and hasno immediate prospects for subleasing the office space. In accordance with ASC360-10, Impairment and Disposal of Long-Lived Assets, the Company performed a recoverability test and determined that the full carrying amount of the associated right-of-use asset wasnot recoverable. Consequently, the Company recognized a non-cash impairment loss of $89 for thethree months ended* March 31, 2026,*which is included as a component of operating expenses, under the caption "General and administrative," in the condensed consolidated statement of operations and comprehensive loss.

In* March 2026,following the abandonment and impairment of the right-of-use asset, the Companyno* longer recognizes a straight-line monthly rent expense, which was recorded as equal to the sum of all fixed lease payments divided by the number of months in the lease term. Instead, the Company continues to recognize the lease liabilities, with subsequent interest accretion recognized as interest expense and the lease payments reducing the lease liabilities. Prior to the impairment loss, the corresponding right of use asset was reflected in the consolidated balance sheets under the caption Right-of-use assets as of* December 31, 2025.*Non-lease components, such as operating costs, are excluded from the lease liability calculation and expensed as incurred.

In* March 2025,the Company entered into an operating lease agreement for its new distribution and service facility in Ratingen, Germany (the "Ratingen Lease"), which commenced in May 2025and expires in April 2030.In May 2025,*the Company moved its administrative office from Hamburg, Germany, which serves EMEA, to this new facility.

The Ratingen Lease constitutes a lease under ASC842, and the Company estimates the lease term as* May 2025through April* 2030. Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company's operating lease agreement for the former office in Hamburg, Germany (the "Hamburg Lease") commenced in* May**2022* and expired in* June 2025.*

The Hamburg Lease constituted a lease under ASC842, and the Company estimated the lease term as* May 2022through June 2025.*Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, were excluded from the lease liability calculation and expensed as incurred. The Company recorded a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.

The Company’s future lease payments as of* March 31, 2026*, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:

Lease expense under the Company’s operating leases was $115 and $157 for thethree months ended* March 31, 2026and2025*, respectively.

19

11. Capitalization and Equity Structure

Reverse Stock Split

Before the opening of the stock market on* June**2,* 2025, the Company effected a1-for-15 reverse split of its common stock (the "Reverse Stock Split"). As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of fifteen, rounded up to the nearest whole share, and all common stock per share amounts have been increased by a factor of fifteen, with the exception of the Company's common stock par value and the Company's authorized shares. Amounts affected include common stock outstanding, restricted stock units, common stock underlying stock options, and warrants.

As previously disclosed, on* December 12, 2024,the Company received a written notice from the Nasdaq Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that because the minimum bid price for the Company’s common stock listed on the Nasdaq Capital Market was below$1.00* per share over the previous30 consecutive business days, the Company didnot meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule5550(a)(2) (the "Minimum Bid Price Requirement"). The Reverse Stock Split was effected in order to raise the per share trading price of the Company's common stock above*$1.00* and regain compliance with the Minimum Bid Price Requirement. On* June**13,* 2025, the Company regained compliance with the Minimum Bid Price Requirement.

Summary

The Company’s authorized capital stock as of* March 31, 2026* and* December 31, 2025* consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. The authorized capital wasnot reduced in connection with the Reverse Stock Split. As of* March 31, 2026* and* December 31, 2025*, there were 3,563 and 3,559 shares of common stock issued and outstanding, respectively, and 6 and 0 shares of preferred stock issued and outstanding, respectively.

**** January 2026Private Placement**

On* January 20, 2026,the Company entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the "Purchasers") pursuant to which the Company agreed to issue and sell, in a private placement (the “January 2026Private Placement”), (i) an aggregate of 5.9 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”) convertible into an aggregate of 712 shares (the “January 2026Conversion Shares”) of common stock of the Company, at a conversion price of $8.22 per share, at the holder's option and subject to certain customary adjustments, and (ii) warrants (the “January 2026Private Placement Warrants”) to purchase up to an aggregate of 356 shares of the Company's common stock at an exercise price of $8.22 per share. Pursuant to the Purchase Agreements and subject to limited exceptions, Purchasers may**not* transfer or execute any short sales involving the Series B Preferred Stock,* January 2026Warrants, January 2026Conversion Shares and shares of the Company's common stock underlying the January 2026Warrants until the earlier of (x)six months following the closing of the January 2026*Private Placement and (y)two trading days after the Company consummates a change of control. The Series B Preferred Stock ranks senior to the Company’s common stock with respect to liquidation preferences and participating dividends and ranks junior to the Company’s indebtedness.

The closing of the* January 2026Private Placement took place on January 22, 2026.The Company received net proceeds of approximately $5,265, after deducting placement agent fees and offering expenses paid by the Company. The Company is using the net proceeds from the January 2026*Private Placement for working capital and general corporate purposes.

In connection with the* January 2026Private Placement, the Company issued to Lake Street Capital Markets, LLC a warrant (the “January 2026*Placement Agent Warrant”) to purchase up to 14 shares of the Company's common stock, at an exercise price equal to $8.22 per share.

**** October 2025Offering**

On* October 30, 2025,the Company issued and sold an aggregate of 769 shares of its common stock in a registered direct offering (the “October 2025Offering”) at an offering price of $4.81 per share. The Company received net proceeds of approximately $3,231 in the October 2025Offering, after deducting the placement agent fees and offering expenses paid by the Company. The Company used the net proceeds from the October 2025*Offering for general corporate purposes, which included research and development activities, selling, general and administrative costs, pursuing strategic initiatives, and meeting its other working capital needs.

On* October 30, 2025,in connection with the October 2025Offering, the Company issued to Lake Street Capital Markets, LLC a warrant (the “October 2025*Placement Agent Warrant”) to purchase up to 15 shares of the Company's common stock, at an exercise price equal to $4.81 per share.

**** March 2025Inducement Warrant Transaction**

On* March 17, 2025,the Company entered into a warrant inducement agreement (the “Inducement Agreement”) with an existing holder (the “Investor”) ofone* of the Company’s Series A common stock purchase warrants andone of the Company's Series B common stock purchase warrants (collectively, the “Existing Investor Warrants”) that the Company issued as part of the* September 2024Offering (as defined below), pursuant to which, among other things, the Investor exercised for cash its Existing Investor Warrants to purchase an aggregate of 653 shares (the “Existing Investor Warrant Shares”) of common stock at a reduced exercise price of $6.36 per share (the “Inducement Exercise”). In consideration for exercising the Existing Investor Warrants, the Company issued to the Investor a new common stock purchase warrant to purchase up to an aggregate of 700 shares of common stock (such warrant, the “Inducement Warrant” and such shares of common stock issuable upon exercise thereof, the “Inducement Warrant Shares”) (collectively, the "March 2025Inducement Warrant"). The Inducement Warrant became exercisable on May 16, 2025,the date the Company received approval from the Company’s stockholders (the “Stockholder Approval Date”) in accordance with the applicable rules and regulations of The Nasdaq Capital Market, and maybe exercised following such date through May 16, 2030,at an exercise price of $6.36 per share. The Company received net proceeds of approximately $3,853 from the March**2025* Inducement Warrant, after deducting the transaction expenses paid by the Company. The Company used the net proceeds from the* March 2025*Inducement Warrant for general corporate purposes, which included growth and expansion of the Company's Personal Health products as the Company worked to increase its revenue following the establishment of Medicare CMS reimbursement of the Ekso Indego Personal device, research and development activities, selling, general and administrative costs, pursuing strategic initiatives, and meeting its other working capital needs.

**** September 2024Offering**

On* August 29, 2024,the Company entered into an underwriting agreement with Craig-Hallum Capital Group LLC as underwriter (the "Underwriter") pursuant to which the Company issued and sold, in a firm commitment underwritten public offering (the "September 2024Offering"),207 shares of common stock, a pre-funded warrant to purchase 193 shares of common stock (the "Pre-Funded Warrant"), Series A common stock purchase warrants to purchase an aggregate of 400 shares of common stock (the "Series A Warrants"), and Series B common stock purchase warrants to purchase an aggregate of 400 shares of common stock (the "Series B Warrants"). The September 2024Offering closed on September 3, 2024.The Company received net proceeds of approximately $5,003 in the September 2024*Offering, after deducting the underwriting discount and commissions and offering expenses paid by the Company.

**** January 2024Offering**

On* January 10, 2024,the Company entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 198 shares of the Company’s common stock in a registered direct offering (the “January 2024Offering”) at an offering price of $23.25 per share. The net proceeds of the January 2024*Offering were approximately $3,932 after deducting placement agent fees and offering expenses paid by the Company.

At the Market Offering

In* October 2020,the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company mayissue and sell shares of its common stock, from time to time, to or through the Agent. Offers and sales of shares of common stock by the Company through the Agent maybe made by any method deemed to be an “at the market offering” as defined under SEC Rule415* or in privately negotiated transactions, subject to certain conditions. Such shares* maybe offered pursuant to the registration statement on Form S-3 (FileNo.* 333-272607) (the “Registration Statement”), which was declared effective by the SEC on* June 20, 2023,and a related prospectus supplement filed with the SEC on July 28, 2023 (the “ATM Prospectus”). Pursuant to the Registration Statement and the ATM Prospectus, shares having an aggregate offering price of up to $5,000 * maybe offered and sold, subject to certain SEC rules limiting the amount of shares of the Company’s common stock that* maybe sold by the Company under the Registration Statement. On October 28, 2025,the Company terminated the ATM Prospectus. As a result, the Company expensed deferred issuance costs of $125 related to the ATM Agreement during the year ended December 31, 2025.For the comparable period, the Company didnot sell any shares under the ATM Agreement during thethree* months ended* March 31, 2025*.

Series B Convertible Preferred Shares and Warrants

** January 2026Series B Preferred Stock

The Series B Preferred Stock includes optional redemption rights, of which: (i) holders* mayrequire cash redemption at the Stated Value upon the suspension of the Company's common stock from trading on its principal trading market for a certain time period or the common stock failing to be listed on its principal trading market, and (ii) at any time after January 22, 2027,the Company or holders may*redeem all or a portion of the shares at the Stated Value, subject to certain exceptions.

While the Series B Preferred Stock meets the equity classification criteria, the redemption features, particularly the time-based redemption right, make it probable of becoming redeemable. Accordingly, the Series B Preferred Stock is classified as Temporary equity (or mezzanine equity) in the Company's condensed consolidated balance sheet as of* March 31, 2026.*

Allocation of January 2026Private Placement Proceeds

The Company determined the fair value of the Series B Preferred Stock to be $7,453 and the fair value of the* January 2026Private Placement Warrants to be $2,053, which were valued using the Binomial Lattice model as of the January 2026Private Placement issuance date. The Company used the residual method to allocate the $5,852 gross proceeds of the Series B Preferred Stock and the January 2026Private Placement Warrants, resulting in $3,799 allocated to the Series B Preferred Stock and $2,053 allocated to the January 2026Private Placement Warrants. The total transaction costs of approximately $670, which include the January 2026Placement Agent Warrant value of $83, have been allocated using the relative fair values of the Series B Preferred Stock and the January 2026Private Placement Warrants. The issuance costs allocated to the Series B Preferred Stock of $525 are accounted for as a reduction to the allocated gross proceeds, and the issuance costs allocated to the January 2026Private Placement Warrants of $145 are expensed. As such, the net carrying amounts recorded at the January 2026Private Placement issuance date were $3,274 for the Series B Preferred Stock (classified as temporary equity) and $2,053 for the January 2026Private Placement Warrants (classified as a warrant liability). Additionally, the January 2026Placement Agent Warrant value of $83 was recorded as a warrant liability and was valued using the Black-Scholes model as of the January 2026Placement Agent Warrant issuance date. See** January 2026Warrants*below for information regarding the liability classification of such warrants.

The Series B Preferred Stock is being accreted to its full redemption value of $5,852 over theone-year period ending* January 20, 2027,*using the effective yield method. Accretion is classified and recorded as a deemed dividend, which increases loss available to common stockholders used for the basic and diluted net loss per common share calculation.

The following table presents the accretion and carrying amount of the Series B Preferred Stock as of* March 31, 2026*:

20

Warrants outstanding as of* March 31, 2026* and* December 31, 2025* were as follows:

() The Inducement Warrant became exercisable upon the Stockholder Approval Date and maybe exercised following such date through May 16, 2030.*

No warrants were exercised during thethree months ended* March 31, 2026*, compared to 824 warrants exercised during the same period of2025. The weighted average exercise price of the warrants outstanding as of* March 31, 2026* was $7.48.

** January 2026Warrants

In* January 2026,the Company issued the January 2026Private Placement Warrants to purchase up to an aggregate of 356 shares of the Company's common stock at an exercise price of $8.22 per share. Each January 2026Private Placement Warrant is exercisable starting on July 22, 2026,subject to certain conditions set forth in the January 2026Private Placement Warrants, including that the holder doesnot* at the time of such exercise hold any shares of the Series B Preferred Stock or the* January 2026*Conversion Shares.

On* January 22, 2026,in connection with the January 2026Private Placement, the Company issued to Lake Street Capital Markets, LLC the January 2026Placement Agent Warrant to purchase up to 14 shares of the Company's common stock, at an exercise price equal to $8.22 per share, in substantially the same form as the January 2026*Private Placement Warrants.

The exercise price of the* January 2026Private Placement Warrants is subject to adjustment in the event of stock dividends, stock splits, stock combinations, reorganizations or similar events affecting the Company's common stock. The January 2026Private Placement Warrant maybe exercised, at the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) if there isnot* an effective registration statement registering, or the prospectus contained therein isnot available for the issuance of, the underlying common stock, a cashless exercise, in which case the holder would receive upon such exercise the net number of common stock determined according to the formula set forth in the* January 2026Private Placement Warrant. However, subject to limited exceptions, a January 2026Private Placement Warrant holder willnot* have the right to exercise any portion of such holder’s* January 2026Private Placement Warrant if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of the Company's common stock in excess of 9.99% (or 19.99% on an aggregate basis with all of the other Purchasers in the January 2026*Private Placement) of the shares of the Company's common stock then outstanding and/or the then combined voting power of all of the Company’s securities immediately after giving effect to such exercise.

The* January 2026Private Placement Warrantsand the January 2026Placement Agent Warrantare classified as warrant liabilities due tonot* being indexed to the Company's common stock. These warrant liabilities were measured at fair value upon issuance and are remeasured to fair value at each reporting date using certain estimated inputs, which are classified within Level3 of the fair value hierarchy. SeeAllocation of January 2026Private Placement Proceedsabove for information regarding the valuation of such warrants. The following assumptions were used in the valuations to measure the fair value of the* January 2026Private Placement Warrants and the January 2026*Placement Agent Warrant:

** January 2026Private Placement Warrants

21

** January 2026Placement Agent Warrant

** October 2025Warrants

In* October 2025,the Company issued the October 2025Placement Agent Warrant, exercisable for up to 15 shares of the Company’s common stock at an exercise price of $4.81 per share. The October 2025Placement Agent Warrant was exercisable immediately and expire on October 30, 2030.*

The* October 2025Placement Agent Warrant maybe exercised, at the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) if there isnot* an effective registration statement registering, or the prospectus contained therein isnot available for the issuance of, the underlying common stock, a cashless exercise, in which case the holder would receive upon such exercise the net number of common stock determined according to the formula set forth in the* October 2025Placement Agent Warrant. However, a holder willnot* be entitled to exercise any portion of the* October 2025Placement Agent Warrant if the holder's ownership of the Company's common stock would exceed 4.99% (the "Beneficial Ownership Limitation"). The holder, upon notice to the Company, mayincrease the Beneficial Ownership Limitation to 9.99%, which increase shallnot* be effective until the61st day after such notice is delivered to the Company.

In the event the Company enters into a Fundamental Transaction, as defined in the* October 2025Placement Agent Warrant, the holder of the October 2025Placement Agent Warrant will be entitled to receive, upon exercise of these warrants, the kind of amounts of securities, cash, or other property that the holder would have received had they exercised these warrants immediately prior to such Fundamental Transaction without regard to the Beneficial Ownership Limitation contained in the October 2025*Placement Agent Warrant.

The* October 2025Placement Agent Warrant is classified as a component of stockholders’ equity within additional paid-in capital and was recorded at the October 2025Offering issuance date. The October 2025Placement Agent Warrant is equity classified because it (i) is a freestanding financial instrument that is legally detachable and separately exercisable from the equity instruments, (ii) is immediately exercisable, (iii) doesnot* embody an obligation for the Company to repurchase its shares, (iv) permits the holder to receive a fixed number of shares of common stock upon exercise, (v) is indexed to the Company’s common stock, and (vi) meets the equity classification criteria. In addition, such* October 2025Placement Agent Warrant doesnot* provide any guarantee of value or return.

** March 2025Inducement Warrant

In* March 2025,the Company issued the Inducement Warrant to purchase up to an aggregate of 700 shares of common stock at an exercise price of $6.36 per share. The Inducement Warrant became exercisable upon the Stockholder Approval Date and maybe exercised following such date through May 16, 2030.*

The Inducement Warrant* maybe exercised, at the holder’s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) if there isnot* an effective registration statement registering, or the prospectus contained therein isnot available for the issuance of, the underlying common stock, a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Inducement Warrant. However, a holder willnot be entitled to exercise any portion of the Inducement Warrant if the holder’s ownership of the Company’s common stock would exceed 4.99% (the “Beneficial Ownership Limitation”). The holder, upon notice to the Company,* mayincrease the Beneficial Ownership Limitation to 9.99%, which increase shallnot* be effective until the61st day after such notice is delivered to the Company.

In the event the Company enters into a Fundamental Transaction, as defined in the Inducement Warrant, the holder will be entitled to receive, upon exercise of the Inducement Warrant, the kind of amounts of securities, cash, or other property that the holders would have received had they exercised these warrants immediately prior to such Fundamental Transaction without regard to the Beneficial Ownership Limitation contained in the Inducement Warrant. In addition, upon a Fundamental Transaction, subject to certain limitations and exceptions, the holder of the Inducement Warrant* mayput the Inducement Warrant back to the Company for an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of the Inducement Warrant, however, if such Fundamental Transaction isnot* considered within control of the Company, andnot approved by the Company's Board of Directors, then the holder of the Inducement Warrant wouldnot be able to put the Inducement Warrant back to the Company for cash.

The Inducement Warrant is classified as a component of stockholders’ equity within additional paid-in capital and was recorded at the* March 2025Inducement Warrant issuance date. The Inducement Warrant is equity classified because it (i) is a freestanding financial instrument that is legally detachable and separately exercisable from the equity instruments, (ii) is immediately exercisable upon stockholder approval, (iii) doesnot* embody an obligation for the Company to repurchase its shares, (iv) permits the holders to receive a fixed number of shares of common stock upon exercise, (v) is indexed to the Company’s common stock, and (vi) meets the equity classification criteria. In addition, the Inducement Warrant doesnot provide any guarantee of value or return.

22

** September 2024Warrants

In* September 2024,the Company issued the Pre-Funded Warrant to purchase 193 shares of common stock, with an exercise price of $0.001 per share, for $2,897 in aggregate cash proceeds, which represents the September 2024Offering price for the common stock of $15.00, less the per share exercise price. The Pre-Funded Warrant was fully exercised as of March 31, 2025.*

In* September 2024,the Company issued the Series A Warrants, which are exercisable for an aggregate of up to 400 shares of the Company’s common stock at an exercise price of $15.00 per share. The Series A Warrants were exercisable immediately and expire on September 4, 2029.*

In* September 2024,the Company issued the Series B Warrants, which were exercisable for an aggregate of up to 400 shares of the Company’s common stock at an exercise price of $15.00 per share. The Series B Warrants were exercisable immediately and expired on September 3, 2025.*

The Series A Warrants* maybe exercised, at the holder’s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) if there isnot* an effective registration statement registering, or the prospectus contained therein isnot available for the issuance of, the underlying common stock, a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Series A Warrant. However, a holder willnot be entitled to exercise any portion of the Series A Warrants if the holder’s ownership of the Company’s common stock would exceed the Beneficial Ownership Limitation. The holder, upon notice to the Company,* mayincrease the Beneficial Ownership Limitation to 9.99%, which increase shallnot* be effective until the61st day after such notice is delivered to the Company.

In the event the Company enters into a Fundamental Transaction, as defined in the applicable Series A Warrant, the holders of the Series A Warrants will be entitled to receive, upon exercise of these warrants, the kind of amounts of securities, cash, or other property that the holders would have received had they exercised these warrants immediately prior to such Fundamental Transaction without regard to the Beneficial Ownership Limitation contained in the Series A Warrant. In addition, upon a Fundamental Transaction, subject to certain limitations and exceptions, the holder of the Series A Warrant* mayput the warrant back to the Company for an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of the Series A Warrant, however, if such Fundamental Transaction isnot* considered within control of the Company, andnot approved by the Company's Board of Directors, then the holder of the Series A Warrant wouldnot be able to put the Series A Warrant back to the Company for cash.

The Series A Warrants are, and the Series B Warrants were, classified as a component of stockholders’ equity within additional paid-in capital and were recorded at the* September 2024Public Offering issuance date. The Series A Warrants are, and the Series B Warrants were, equity classified because they (i) are freestanding financial instruments that were legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) donot* embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company’s common stock, and (vi) meet the equity classification criteria. In addition, such Series A Warrants donot provide any guarantee of value or return.

2021 Warrants

In* February 2021,the Company issued warrants (the"2021* Warrants"), exercisable for up to 18 shares of the Company’s common stock at an exercise price of $192.19 per share. The2021 Warrants were exercisable immediately and expired on* February 11, 2026.The2021* Warrants* maybe exercised, at the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) if there isnot* an effective registration statement registering, or the prospectus contained therein isnot available for the issuance of, the underlying common stock, a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the2021 Warrant. However, a holder willnot be entitled to exercise any portion of the2021 Warrants if the holder’s ownership of the Company’s common stock would exceed the Beneficial Ownership Limitation. The holder, upon notice to the Company,* mayincrease the Beneficial Ownership Limitation to 9.99%, which increase shallnot* be effective until the61st day after such notice is delivered to the Company.

The warrant liability related to the2021 Warrants was measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes model to measure the fair value of the2021 Warrants:

23

12. Stock-based Compensation

Shares available for grant

On* May 16, 2025,the Company held its2025* Annual Meeting of Stockholders (the "Annual Meeting") and ratified an amendment to the Company's Amended and Restated2014 Equity Incentive Plan (the*"2014* Plan") to increase the total number of shares of common stock authorized for issuance by 153 shares. As of* March 31, 2026*, the total number of shares authorized for grant under the2014 Plan was 468, of which approximately 1 were available for future grants.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) to employees and non-employees. Each RSU represents the right to receiveone share of the Company’s common stock upon vesting and subsequent settlement. The fair values of RSUs are determined based on the closing price of the Company’s common stock on the date of grant.

RSU activity for thethree months ended* March 31, 2026* is summarized below:

The total grant-date fair value of RSUs that vested during thethree months ended* March 31, 2026was $32. As of March 31, 2026*, $173 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 1.12 years.

24

Stock Options

The following table summarizes information about the Company's stock options outstanding as of* March 31, 2026*:

No stock options were granted or exercised during thethree months ended* March 31, 2026and2025*.

Asno stock options were granted during thethree months ended* March 31, 2026and2025,* there wasno related weighted-average grant date fair value. The total grant date fair value of stock options vested during thethree months ended* March 31, 2026and2025* was $0.

As of* March 31, 2026*, total unrecognized compensation cost related to unvested stock options was $0.

Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to RSUs was recorded as follows:

401(k) Plan Share Match

During thethree months ended* March 31, 2026,the Company paid $265 in cash to eligible employees’ deferral accounts for the Ekso Bionics401*(k) plan (the*"401*(k) Plan") matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the year ended* December 31, 2025.*

During thethree months ended* March 31,2025, the Company issued 37 shares of common stock with a fair value of $236 to eligible employees’ deferral accounts for the401(k) Plan matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the year ended December 31,2024. The expense, net for the401(k) Plan share matching was $(25) for thethree months ended March 31, 2025.*

25

13. Income Taxes

There wereno material changes to the unrecognized tax benefits in thethree months ended* March 31, 2026* and2025, and the Company doesnot expect significant changes to unrecognized tax benefits through the end of the fiscal year ending* December 31, 2026.*

14. Commitments and Contingencies

Material Contracts

The Company hastwo license agreements with the Regents of the University of California to maintain exclusive rights to certain patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license.

The Company hasone license agreement with Vanderbilt University to maintain exclusive rights to patents on the Company's behalf. Under the Vanderbilt Exoskeleton License Agreement, the Company is required to pay 6% of net sales of licensed patent products and 3% of net sales of licensed software products. The minimum annual royalty for licensed products is $250. The Vanderbilt Exoskeleton License Agreement will continue until* April 29, 2038,*unless sooner terminated.

Purchase Obligations

The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction.

The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling$1,385 as of* March 31, 2026*, which are expected to be paid withinone year, and $874 as of* December 31, 2025*. Timing of payments and actual amounts paid* may*be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.

The Company has operating lease commitments totaling $503 payable over the lease terms of the San Rafael Lease, the Ohio Lease, and the Ratingen Lease as disclosed in Note9. Lease Obligations.

Loss Contingencies

In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters willnot have a material adverse effect on the Company’s condensed consolidated financial statements.

26

15. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per common share:

() For thethree* months ended* March 31, 2026,the deemed dividend represents the periodic accretion of the redeemable Series B Preferred Stock's carrying amount to its full redemption value of $5,852, which increases loss available to common stockholders used for the basic and diluted net loss per common share calculation. Refer to Note11.* Capitalization and Equity Structure – Series B Convertible Preferred Shares and Warrants for additional information regarding the* January 2026*Series B Preferred Stock.

(**) For thethree months ended* March 31, 2025,the deemed dividend represents the Company's incremental fair value of the March 2025Inducement Warrant over the gross proceeds received, which increases loss available to common stockholders used for the basic and diluted net loss per common share calculation. Refer to Note11.* Capitalization and Equity Structure – Series B Convertible Preferred Shares and Warrants for additional information regarding the* March 2025*Inducement Warrant.

The following table sets forth potential shares of common stock that arenot included in the calculation of diluted net loss per common share because to do so would be anti-dilutive as of the end of each period presented:

16. Segment Disclosures

Operating segments are defined as components of a public entity for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company's CODM is its chief executive officer who reviews financial information, annual operating plans, and long-range forecasts, presented on a consolidated basis, for purposes of making operating decisions, evaluating financial performance, and allocating resources. The Company is managed as asingle operating segment that primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility in the healthcare market. Managing the Company's business activities on a consolidated basis allows the Company to benefit from the value its healthcare products provide across the care continuum.

The Company’s CODM uses net loss as presented on the consolidated statements of operations and comprehensive loss to measure segment loss and assesses financial performance against expectations for the Company's single reportable segment to decide how to allocate resources. Additionally, the CODM reviews and uses segment expenses included in net loss to manage the Company’s operations and assess operating performance. The measure of segment assets is reported on the Company's consolidated balance sheets as total assets. The significant segment expenses regularly provided to the CODM are those presented on the consolidated statements of operations and comprehensive loss. These significant segment expenses include cost of revenue, sales and marketing, research and development and general and administrative expenses. Other segment items that are presented on the consolidated statements of operations and comprehensive loss include interest expense, net, (loss) gain on revaluation of warrant liabilities, finance cost associated with warrant issuance, unrealized (loss) gain on foreign exchange and other expense, net.

27

**17. ** Related Party Transactions

There wereno related party transactions during thethree months ended* March 31, 2026* and2025.